TED Member States· European UniontenderOpen · 09 Nov 2026
HUMANIZED MONOCLONAL ANTIBODY being an inhibitor of the tissue factor-dependent coagulation pathway - concizumab along with successive deliveries to hemophilia treatment centers and related bleeding disorders and patients' homes
Narodowe Centrum Krwi
Tenders due 09 Nov 2026Tenders due09 Nov 2026
CPV category33621000
Published22 Oct 2026
Reference736137-2026
Notice summary
The subject of the order includes the delivery to Direct Recipients (Hemophilia Treatment Centers and Related Bleeding Disorders) of a humanized monoclonal antibody being an inhibitor of the tissue factor-dependent coagulation pathway - concizumab along with administration sets - hereinafter referred to as 'medicinal product', in order to secure the treatment of patients with hemophilia type B complicated by an inhibitor, as part of the implementation of the health policy pro…
Is this worth bidding on?
Tender Radar scores every tender against your company profile, surfaces the matching services, and flags the ones worth your time — across Europe and beyond. Sign in to see the relevance match and full AI analysis for this opportunity.